News

Women with BRCA-mutated (BRCAm) advanced ovarian cancer treated 1st-line with Lynparza maintenance therapy had a statistically-significant and clinically-meaningful improvement in progression-free survival compared to placebo. The safety and tolerability

The approval is for patients with unresectable or metastatic melanoma and who are positive to BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. Array BioPharma said the

This deal builds on the VivaGel® BV licence signed with Mundipharma in May 2018 for Asia, the Middle East, Africa and parts of Latin America. Mundipharma is a

The study assessed Ibrance in combination with fulvestrant against placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer

The collaboration will evaluate IPI-549 in combination with AB928, Arcus's dual adenosine receptor antagonist, and AB122, Arcus's anti-PD-1 antibody, as well as IPI-549 in combination with AB928 and

The CHMP’s opinion is for the approval of the drug’s marketing authorisation application (MAA) for the extended adjuvant treatment of early stage HER2-positive hormone receptor positive breast cancer.

Zemdri, which is an intravenous infusion and administered once daily, was approved to treat adults with cUTI, including pyelonephritis, caused by certain Enterobacteriaceae in patients who have limited or

This collaboration broadens AbbVie’s oncology research to access advanced precision medicine technology to expand the development of potentially life-changing treatments for patients with cancer. Chimeric Antigen Receptor T-cell

The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose